Balance Sheet
Cash Flow Statement
Cash from Financing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Rein Therapeutics (RNTX) Cash from Operations (2016 - 2025)

Rein Therapeutics (RNTX) has disclosed Cash from Operations for 10 consecutive years, with 3548000.0 as the latest value for Q3 2025.

  • On a quarterly basis, Cash from Operations rose 7.1% to 3548000.0 in Q3 2025 year-over-year; TTM through Sep 2025 was 20953000.0, a 24.82% increase, with the full-year FY2024 number at 22291000.0, down 12.54% from a year prior.
  • Cash from Operations was 3548000.0 for Q3 2025 at Rein Therapeutics, up from 6418000.0 in the prior quarter.
  • In the past five years, Cash from Operations ranged from a high of 1640000.0 in Q3 2023 to a low of 10391000.0 in Q4 2023.
  • A 5-year average of 5624157.89 and a median of 5685000.0 in 2022 define the central range for Cash from Operations.
  • Peak YoY movement for Cash from Operations: surged 76.47% in 2023, then tumbled 169.22% in 2024.
  • Rein Therapeutics' Cash from Operations stood at 6255000.0 in 2021, then rose by 29.51% to 4409000.0 in 2022, then plummeted by 135.68% to 10391000.0 in 2023, then soared by 53.69% to 4812000.0 in 2024, then rose by 26.27% to 3548000.0 in 2025.
  • Per Business Quant, the three most recent readings for RNTX's Cash from Operations are 3548000.0 (Q3 2025), 6418000.0 (Q2 2025), and 6175000.0 (Q1 2025).